Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical-stage medical device innovator advancing the Hemopurifier® - a therapeutic filtration device targeting cancer-enabling exosomes and life-threatening viruses. This page provides investors and medical professionals with essential updates on clinical developments, regulatory progress, and strategic initiatives.
Key resources include press releases detailing trial protocols, ethics committee approvals, and operational milestones. Users will find verified information on oncology applications for treatment-resistant cancers and infectious disease programs, all presented in compliance with financial disclosure standards.
Content highlights encompass FDA communications, trial enrollment updates, and peer-reviewed research collaborations. The curated news collection serves as a reliable reference for tracking the Hemopurifier®'s progress through clinical validation stages and potential therapeutic applications.
Bookmark this page for direct access to Aethlon Medical's official announcements, including breakthrough device designations and international trial expansions. Check regularly for updates on this pioneering approach to blood filtration technology and its implications for cancer immunotherapy advancement.
Aethlon Medical (NASDAQ: AEMD) has received full ethics approval from the Bellberry Human Research Ethics Committee for a clinical trial of its Hemopurifier® at Pindara Private Hospital in Queensland, Australia. The trial will study the safety, feasibility, and dosing of the Hemopurifier in patients with solid tumors not responding to anti-PD-1 antibodies like Keytruda® or Opdivo®. This is the second ethics approval for the oncology trial in Australia, following approval at Royal Adelaide Hospital in June.
The trial aims to enroll 9-18 patients and will focus on safety as the primary endpoint. It will also explore the Hemopurifier's ability to reduce extracellular vesicles (EVs) in cancer patients' blood, which may improve response rates to anti-PD-1 therapies. The study results are expected to inform the design of a future Premarket Approval (PMA) study.
Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company developing products for cancer and infectious diseases, has announced its fiscal first quarter financial results release and conference call for August 14, 2024. The company will issue financial results for the quarter ended June 30, 2024, at 4:15 p.m. ET, followed by a conference call at 4:30 p.m. ET. Management will review financial results and recent corporate developments, with a subsequent Q&A session. Interested parties can register online or dial in directly. A replay will be available until September 14, 2024, accessible via Aethlon's website or by phone.
Aethlon Medical (Nasdaq: AEMD) announced financial results for the fiscal year ending March 31, 2024, and provided a corporate update. The company continues the clinical development of its Hemopurifier® for cancer and infectious diseases, receiving ethics approval for a clinical trial in Australia. Financially, Aethlon reported a net loss of $12.2 million, a slight increase from the previous year's $12 million. Operating expenses rose marginally to $12.6 million from $12.5 million, driven by increased payroll costs. The current cash balance stands at $9.1 million. Efforts are ongoing to secure approvals for additional trial sites in Australia and India, with patient enrollment expected by late 2024.
Aethlon Medical (Nasdaq: AEMD) will release its fiscal year-end financial results on June 27, 2024, at 4:15 p.m. ET. The company focuses on developing therapeutic products for cancer and serious infectious diseases.
Management will host a conference call the same day at 4:30 p.m. ET to discuss the financial results and recent corporate developments. The call will include a Q&A session.
Participants can register for the call at https://dpregister.com/sreg/10190237/fce977aef1, where they will receive dial-in numbers. Those without internet access can dial in toll-free at 1-844-836-8741 or internationally at 1-412-317-5442.
A replay of the call will be available until July 27, 2024, via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international), using replay conference ID 6876352.
Investorideas.com has released an industry snapshot on the future treatment of solid cancer tumors, highlighting Aethlon Medical's (NASDAQ: AEMD) advancements. Aethlon announced the Human Research Ethics Committee's approval for a clinical trial of its Hemopurifier in cancer patients with stable or progressive disease during anti-PD-1 therapy, valid until June 2027. This trial aims to improve responses to treatments like Keytruda and Opdivo by removing extracellular vesicles from the bloodstream. The Hemopurifier has shown promise in preclinical studies, reducing exosomes in cancer patient samples. The trial, led by Prof. Michael Brown in Adelaide, Australia, will evaluate safety and treatment efficacy over two months. The market for solid tumor therapeutics is projected to grow from USD 222.71 billion in 2023 to USD 885.44 billion within ten years, driven by increased R&D investments. Key developments include AbbVie's acquisition of ImmunoGen and significant advancements in their antibody-drug conjugate platform.
Aethlon Medical received ethics approval from the Human Research Ethics Committee of the Central Adelaide Local Health Network for its Hemopurifier® cancer trial. The trial, focusing on safety, feasibility, and dose-finding, targets cancer patients with solid tumors unresponsive to anti-PD-1 antibodies. Conducted by Prof. Michael Brown's team in Adelaide, Australia, the study aims to reduce extracellular vesicles to improve therapeutic responses. The approval is valid until June 13, 2027. The primary endpoint is safety, with patient enrollment following a two-month PD-1 antibody monotherapy period. Aethlon plans to seek additional approvals in Australia and India.
Investorideas.com has released a two-part series on virus treatment developments, featuring Aethlon Medical's (NASDAQ: AEMD) Hemopurifier®. The Hemopurifier® is a breakthrough device for cancer and viral disease treatment, recognized by the FDA. Recent updates include phase 1 clinical trials for cancer patients who are unresponsive to anti-PD-1 therapy. The device has shown potential in treating various viruses in vitro, including HIV, Ebola, and H5N1 bird flu. Zacks reported rising vaccine stocks due to growing bird flu threats. Other companies like ImmunityBio and Aligos Therapeutics are also advancing in viral treatments. This news follows WHO's alert on a new H5N2 bird flu strain causing a human death in Mexico.
Investorideas.com highlights advancements in blood purification medical devices, focusing on Aethlon Medical's (NASDAQ: AEMD) Hemopurifier®. The global blood purification market is projected to grow from USD 17.8 billion in 2021 to USD 29.2 billion by 2030. Aethlon plans Phase 1 trials in Australia and India for patients with stable or progressive solid tumors not responding to anti-PD-1 therapies. The Hemopurifier® aims to remove cancer-promoting exosomes and viruses. The FDA has designated it a 'Breakthrough Device' for specific cancers and viral infections. Data from recent in vitro studies support its efficacy in removing extracellular vesicles from cancer patient plasma, facilitating further clinical trials.
Aethlon Medical is advancing its phase 1 clinical trials for the Hemopurifier®, aimed at patients with solid tumors unresponsive to anti-PD-1 treatments like Keytruda® or Opdivo®.
Progress includes the integration of new in vitro data showing exosome removal from cancer patient plasma, which has been included in documentation for Ethics Committees. Submissions have been made to Ethics Boards in Australia and India, with one site already submitting on May 24, 2024.
Once approvals are received, Clinical Trial Agreements will be finalized, and patient recruitment can begin. The trials focus on safety, feasibility, and dose-finding.
Aethlon Medical (Nasdaq: AEMD), a therapeutic company specializing in cancer and infectious disease treatments, announced a public offering priced at $0.58 per share. This includes 8,100,000 common shares, Class A and Class B warrants to purchase up to 8,100,000 shares each. The Class A warrants expire in five years and Class B in one year. Gross proceeds are expected to be $4.7 million before expenses, with funds directed towards clinical trials, R&D, capital expenditures, and working capital. Closing is anticipated by May 17, 2024. Maxim Group is the exclusive placement agent.
FAQ
What is the current stock price of Aethlon Medical (AEMD)?
What is the market cap of Aethlon Medical (AEMD)?
